Clinical Trial Update: Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating dovitinib in combination with fulvestrant for postmenopausal women with HER2-negative, hormone receptor-positive metastatic breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dovitinib (dovitinib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-07-11